{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:03:37Z","timestamp":1773903817848,"version":"3.50.1"},"reference-count":48,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common dose-limiting side effects of chemotherapeutic drugs. Numerous clinical trials of various targeted drugs for the prevention or treatment of CIPN have been conducted; however, previous systematic reviews with direct comparisons have failed to demonstrate the efficacy of these drugs in the prevention or treatment of CIPN. In addition, no systematic reviews have indirectly compared CIPN prevention and treatment. This article describes a protocol for evaluating the efficacy and safety of drug therapy for the prevention and treatment of CIPN. The results of the proposed systematic review with network meta-analysis (NMA) will provide new insights into the prevention and treatment of CIPN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will conduct a literature search in MEDLINE, PubMed, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov to find relevant articles published through January 2023. We will include studies that investigated the efficacy and safety of vitamin B<jats:sub>12<\/jats:sub>, goshajinkigan, non-steroidal anti-inflammatory analgesics, opioids, calcium and magnesium, antidepressants and anticonvulsants on CIPN. Two authors will individually screen the retrieved reports and review the full text based on the selection criteria. The primary outcome is the incidence and severity of CIPN. The risk of bias will be assessed using V.2.0 of the Cochrane risk-of-bias tool. We will apply a frequentist random-effects NMA model to pool effect sizes across trials using risk ratios and mean differences with their 95% CIs. Competing interventions will be ranked using the surface under cumulative ranking probabilities. Heterogeneity will be assessed using the heterogeneity variance \u03c4<jats:sup>2<\/jats:sup>, Cochran\u2019s Q test and I\u00b2 statistic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This review does not require ethical approval. The research will be published in a peer-reviewed journal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022371829.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070645","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T20:41:05Z","timestamp":1694551265000},"page":"e070645","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of drug therapy for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a protocol for a systematic review and network meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2007","authenticated-orcid":false,"given":"Miki Takenaka","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Showa University School of Pharmacy, Shinagawa-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center (SURAC), Showa University, Shinagawa-ku, Tokyo, Japan"},{"name":"Division of Nephrology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-9949","authenticated-orcid":false,"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Data Science, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, Showa University School of Pharmacy, Shinagawa-ku, Tokyo, Japan"},{"name":"Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-7441","authenticated-orcid":false,"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"Global Health Nursing, Graduate School of Nursing Science, St Luke's International University, Chuo-ku, Tokyo, Japan"},{"name":"Tokyo Foundation for Policy Research, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"2025101812123963000_13.9.e070645.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"2025101812123963000_13.9.e070645.2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007853"},{"key":"2025101812123963000_13.9.e070645.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.8533"},{"key":"2025101812123963000_13.9.e070645.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"2025101812123963000_13.9.e070645.5","first-page":"2241","article-title":"Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer","volume":"25","author":"Song","year":"2017","journal-title":"Support Care Cancer"},{"key":"2025101812123963000_13.9.e070645.6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/1673-5374.198986","article-title":"Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage","volume":"12","author":"Kelley","year":"2017","journal-title":"Neural Regen Res"},{"key":"2025101812123963000_13.9.e070645.7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz011"},{"key":"2025101812123963000_13.9.e070645.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment Methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"key":"2025101812123963000_13.9.e070645.9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.6004\/jnccn.2021.7026","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes","volume":"19","author":"Battaglini","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025101812123963000_13.9.e070645.10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol"},{"key":"2025101812123963000_13.9.e070645.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.004"},{"key":"2025101812123963000_13.9.e070645.12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2018.12.015","article-title":"L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a perspective on targeting Nrf-2 and NF-\u039aB pathways","volume":"365","author":"Yehia","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025101812123963000_13.9.e070645.13","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170915143217"},{"key":"2025101812123963000_13.9.e070645.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8738"},{"key":"2025101812123963000_13.9.e070645.15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3889\/oamjms.2018.333","article-title":"Comparison of the effects of omega 3 and vitamin E on palcitaxel-induced peripheral neuropathy","volume":"6","author":"Anoushirvani","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"2025101812123963000_13.9.e070645.16","doi-asserted-by":"crossref","unstructured":"Albers JW , Chaudhry V , Cavaletti G , et al . Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014:CD005228. doi:10.1002\/14651858.CD005228.pub4","DOI":"10.1002\/14651858.CD005228.pub4"},{"key":"2025101812123963000_13.9.e070645.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"2025101812123963000_13.9.e070645.18","first-page":"3489","article-title":"Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain","volume":"24","author":"Solomon","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025101812123963000_13.9.e070645.19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/etm.2011.375","article-title":"Objective evaluation of the alleviating effects of goshajinkigan on peripheral neuropathy induced by paclitaxel\/carboplatin therapy: a multicenter collaborative study","volume":"3","author":"Kaku","year":"2012","journal-title":"Exp Ther Med"},{"key":"2025101812123963000_13.9.e070645.20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/128726","article-title":"Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial","volume":"2014","author":"Watanabe","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025101812123963000_13.9.e070645.21","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916656382","article-title":"Go-sha-Jinki-gan (GJG) ameliorates allodynia in chronic constriction injury-model mice via suppression of TNF-\u0391 expression in the spinal cord","volume":"12","author":"Nakanishi","year":"2016","journal-title":"Mol Pain"},{"key":"2025101812123963000_13.9.e070645.22","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.247551"},{"key":"2025101812123963000_13.9.e070645.23","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130126"},{"key":"2025101812123963000_13.9.e070645.24","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0057-y"},{"key":"2025101812123963000_13.9.e070645.25","doi-asserted-by":"publisher","DOI":"10.1042\/BST0380525"},{"key":"2025101812123963000_13.9.e070645.26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0356-09.2009"},{"key":"2025101812123963000_13.9.e070645.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-09069-9","article-title":"Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients","volume":"21","author":"Sugimoto","year":"2021","journal-title":"BMC Cancer"},{"key":"2025101812123963000_13.9.e070645.28","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13013"},{"key":"2025101812123963000_13.9.e070645.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-9010-y"},{"key":"2025101812123963000_13.9.e070645.30","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.183"},{"key":"2025101812123963000_13.9.e070645.31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1254\/jphs.12006SC","article-title":"Repeated administration of amitriptyline reduces oxaliplatin-induced mechanical allodynia in rats","volume":"118","author":"Sada","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"2025101812123963000_13.9.e070645.32","doi-asserted-by":"publisher","DOI":"10.2165\/11594710-000000000-00000"},{"key":"2025101812123963000_13.9.e070645.33","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0b013e3181df2645"},{"key":"2025101812123963000_13.9.e070645.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.4154"},{"key":"2025101812123963000_13.9.e070645.35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/138161206775474468","article-title":"Na+ channel pharmacology and molecular mechanisms of gating","volume":"12","author":"Yamaoka","year":"2006","journal-title":"Curr Pharm Des"},{"key":"2025101812123963000_13.9.e070645.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2408-8"},{"key":"2025101812123963000_13.9.e070645.37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10147-017-1229-4","article-title":"Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"23","author":"Hoshino","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2025101812123963000_13.9.e070645.38","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2022-003815"},{"key":"2025101812123963000_13.9.e070645.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025101812123963000_13.9.e070645.40","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025101812123963000_13.9.e070645.41","unstructured":"U.S. Department of Health and Human Services . Common terminology criteria for adverse events v5.0 (CTCAE), . 2017 Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"2025101812123963000_13.9.e070645.42","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0298-z"},{"key":"2025101812123963000_13.9.e070645.43","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyl016"},{"key":"2025101812123963000_13.9.e070645.44","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025101812123963000_13.9.e070645.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012"},{"key":"2025101812123963000_13.9.e070645.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025101812123963000_13.9.e070645.47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025101812123963000_13.9.e070645.48","unstructured":"Higgins JPT , Page MJ , Elbers RG , et al . Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT , Thomas J , Chandler J , et al ., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane. 2022. Available: www.training.cochrane.org\/handbook"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:12:49Z","timestamp":1760814769000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,12]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjopen-2022-070645"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070645","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}